| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 May 2026 | 5 May 2026 |
| Audited Results & Final Dividend We would like to inform you that the Board Meeting of the Company was held today i.e. on Tuesday, May 12, 2026, at the registered office of the Company. In pursuance of Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved items as mentioned in the attachment. (As Per BSE Announcement Dated on : 12.05.2026) | ||
| Board Meeting | 10 Feb 2026 | 3 Feb 2026 |
| Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 inter alia to consider and approve 1. The Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31 2025. 2. The Interim Dividend if any for the financial year 2025-2026. The Board Meeting of Bliss GVS Pharma Limited (the Company) was held today i.e. Tuesday, February 10, 2026, at the registered office of the Company has considered and approved the following matter(s) amongst others- 1. Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025. A copy of unaudited Standalone and Consolidated Financial Results of the Company, along with the Limited Review Report of the Auditors of the Company for the quarter and nine months ended December 31, 2025, are enclosed herewith as Annexure-1; and 2. Declared the Interim dividend of 50% i.e. 0.50 paisa per equity share on face value of Re.1/- each for the financial year 2025-2026. The Interim Dividend shall be paid within 30 days from the date of its declaration. (As Per BSE Announcement Dated on:10.02.2026) | ||
| Board Meeting | 23 Dec 2025 | 23 Dec 2025 |
| We would like to inform you that, the Board Meeting of the Company was held today i.e. on Tuesday, December 23, 2025, at the registered office of the Company through Video Conferencing. In pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the matters as enclosed herewith. | ||
| Board Meeting | 6 Nov 2025 | 29 Oct 2025 |
| Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30 2025. Please find attached herewith the Outcome of Board Meeting held on Thursday, November 06, 2025. Please find attached the Resignation of Mr. Gagan Harsh Sharma, Managing Director of the Company with effect from November 06, 2025. (As Per BSE Announcement Dated on 06.11.2025) | ||
| Board Meeting | 30 Sep 2025 | 30 Sep 2025 |
| We would like to inform you that the Board has considered and approved the appointment of Mr. Narsimha Shibroor Kamath, Promoter of the Company, as Chief Executive Officer of the Company with effect from September 30, 2025 | ||
| Board Meeting | 29 Jul 2025 | 22 Jul 2025 |
| Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2025. Please find enclosed intimation in this regard We would like to inform you that, the Board Meeting of the Company was held today i.e. on Tuesday, July 29, 2025 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025. A copy of unaudited standalone and consolidated financial results along with the Limited Review Report of the Auditors. We wish to inform you that the Board of Directors at its meeting held today i.e. Tuesday, July 29, 2025 has considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. (As Per BSE Announcement Dated on :29.07.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
